Volume 1.27 | Oct 26

Pancreatic Cell News 1.27, October 26, 2010.


Production of Functional Glucagon-Secreting Alpha Cells from Human Embryonic Stem Cells  ShareThis
Results indicate that fully differentiated pancreatic endocrine cells can be created via step-wise differentiation of human embryonic stem cells. [Diabetes]



Interested in recruiting talented individuals? Post your career opportunities in Pancreatic Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @PancreaticCell


Sins of the Father
Medical researchers have for the first time shown a link between a father’s weight and diet at the time of conception and an increased risk of diabetes in his offspring. [Press release from The University of New South Wales discussing online prepublication in Nature]

Brain Might Be Key to Leptin’s Actions Against Type 1 Diabetes
New findings suggest a novel role for the brain in mediating beneficial actions of the hormone leptin in type 1 diabetes. [Press release from the University of Texas Southwestern Medical Center discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Scientists Create Australia’s First Diabetes Cells
In a major research advance, Melbourne researchers have created Australia’s first type 1 diabetes cells. Researchers created the diabetes cells using induced pluripotent stem cell technology. [Monash Institute of Medical Research Press Release]

MesenCult®-XF Medium  
Culture Human Mesenchymal Stem Cells in
Xeno-Free MesenCult®-XF

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Chronic High-Fat Diet in Fathers Programs Beta Cell Dysfunction in Female Rat Offspring
Researchers show that paternal high-fat-diet exposure programs beta cell ‘dysfunction’ in rat F1 female offspring. [Nature]

Leptin Therapy Improves Insulin-Deficient Type 1 Diabetes by Central Nervous System-Dependent Mechanisms in Mice
Results unveil a key role for the brain in mediating the antidiabetic actions of leptin in the context of type 1 diabetes. [Proc Natl Acad Sci U S A]
Glucose-Responsive Beta Cells in Islets Isolated from a Patient with Long-Standing Type 1 Diabetes Mellitus
Researchers report in vitro observations on islets isolated from a cadaveric donor who had type 1 diabetes mellitus for 13 years. [Diabetologia]

Long-Term Treatment with Atrial Natriuretic Peptide Inhibits ATP Production and Insulin Secretion in Rat Pancreatic Islets
Atrial natriuretic peptide was investigated for short- and long-term effects on insulin secretion and mechanisms regulating secretion in isolated rat pancreatic islets. [ Am J Physiol Endocrinol Metab]
Long-Term Follow-Up of Patients with Type 1 Diabetes Transplanted with Neonatal Pig Islets
Researchers show the clinical outcome of patients with type 1 diabetes transplanted with neonatal pig islets without immunosuppression. [Clin Exp Immunol]


Identification of Susceptibility Loci in a Mouse Model of KRASG12D-Driven Pancreatic Cancer
Findings provide evidence that regions of chromosomes 2, 4, and 12 influence the development and progression of pancreatic neoplasms initiated by an oncogenic allele of KRAS in mice. [Cancer Res]

Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer
Researchers tested two promising classes of noncytotoxic drugs, synthetic oleanane triterpenoids and rexinoids, for the prevention of carcinogenesis in the highly relevant LSL-KrasG12D/+;LSL-Trp53R127H/+;Pdx-1-Cre mouse model of pancreatic cancer. [Cancer Prev Res]
Polyetheylenimine-Polyplexes of Spiegelmer NOX-A50 Directed Against Intracellular High Mobility Group Protein A1 (HMGA1) Reduce Tumor Growth In Vivo
Results demonstrate that intracellular targets can be successfully addressed with a Spiegelmer using polyethylenimine-based delivery and underline the importance of HMGA1 as a therapeutic target in pancreatic cancer. [J Biol Chem]
Modified Vaccinia Ankara Expressing Survivin Combined with Gemcitabine Generates Specific Antitumor Effects in a Murine Pancreatic Carcinoma Model
Data suggest that vaccination with modified vaccinia Ankara-survivin in combination with gemcitabine represents an attractive strategy to overcome tumor-induced peripheral immune tolerance, and this effect has potential for clinical benefit in pancreatic cancer. [ Cancer Immunol Immunother]
Tailored Alpha-Methylene-Gamma-Butyrolactones and Their Effects on Growth Suppression in Pancreatic Carcinoma Cells
Beta, gamma-diaryl-alpha-methylene-gamma-butyrolactones, particularly those with a trans-relationship exhibited higher potency than parthenolide and LC-1 against all three human pancreatic cancer cell lines. [Bioorg Med Chem Lett]


Collaboration and Option Agreement in Diabetes Research
The Max Planck Institute of Biochemistry in Martinsried and pharmaceutical company GlaxoSmithKline, have signed a research collaboration agreement on the development of novel medicines for the treatment of type II diabetes. [Max Planck Society Press Release Press Release]
Sanofi-aventis Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Genzyme
Sanofi-aventis announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi-aventis’ proposed acquisition of Genzyme Corporation has expired. [Sanofi-aventis Press Release]
CIRM Funds $72 Million to Translate Basic Discoveries into New Therapies, Recruit Stem Cell Leaders to California
The California Institute for Regenerative Medicine (CIRM) approved funding for 19 awards worth $67 million in its second round of awards designed to move good ideas out of the lab and into the clinic. [The California Institute for Regenerative Medicine Press Release]
Two Researchers from Max Delbrück Center and Charité-Universitätsmedizin Receive Million Euro Starting Grants from the European Research Council
Two European Research Council (ERC) Starting Grants worth almost one and a half million Euros each over the next five years have been awarded. American Diabetes researcher Dr. Matthew Poy belongs to the 427 researchers the ERC has chosen from more than 2873 applicants this year. [Max Delbrück Center for Molecular Medicine Berlin-Buch Press Release]

MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
MacroGenics, Inc. and Eli Lilly and Company announced that the Protege Data Monitoring Committee, composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase III clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes. [Eli Lilly and Company Press Release]

Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for Bydureon™
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application for Bydureon™ (exenatide extended-release for injectable suspension). [Eli Lilly and Company Press Release]
Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug
Lotus Pharmaceuticals, Inc. announced that its wholly owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a patent by the State Intellectual Property Office of the People’s Republic of China for controlled-release oral gliclazide. [Lotus Pharmaceuticals, Inc. Press Release]
Eurand Presents Data on ZENPEP® Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients with CF and Pancreatic Insufficiency
Eurand Pharmaceuticals, Inc. announced additional data from a post-hoc analysis of a Phase III clinical trial with ZENPEP® (pancrelipase) Delayed-Release Capsules, an FDA-approved pancreatic enzyme product for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis (CF) or other conditions. [Eurand Pharmaceuticals, Inc. Press Release]
Diamyd Divides Operations into Two Business Areas; Diabetes and Pain
Diamyd Medical states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year: Diabetes and Pain. The Diabetes business area consists of the antigen-based candidate drug Diamyd® for the treatment and prevention of autoimmune diabetes. [Diamyd Medical Press Release]
Glaxo Subpoenaed on Avandia in U.S.
GlaxoSmithKline PLC said net profit fell 3.5% in the third quarter due to frugal government health-care spending and other factors, and disclosed that it has been subpoenaed by U.S. authorities examining its diabetes drug Avandia. [The Wall Street Journal]


Just a Flesh Wound? U.K. Science Budget Spared Deep Cuts
The U.K. government’s long-awaited Comprehensive Spending Review (CSR) was released, and it calls for a flat science budget over the next 4 years. While inflationary costs mean that the budget will likely see a cut of about 10% in real terms over that period, this scenario is far less dramatic than rumored cuts of 20% to 30% in real cash. [HM Treasury, United Kingdom]
Class 3 Drug Alert (Action within 5 days): GlaxoSmithKline / Parallel Distributors – Avandia 4mg, Avandia 8mg, Avandamet 1mg/500mg, Avandamet 2mg/500mg, Avandamet 2mg/1000mg, Avandamet 4mg/1000mg – EL(10)A/20
Following the European Medicines Agency (EMA) recommendation on 23 September 2010 to suspend marketing authorizations for all products containing rosiglitazone across Europe, GlaxoSmithKline announced in its letter to healthcare providers dated 1 October 2010 that all presentations of Avandia and Avandamet would no longer be available after 21 October 2010. [Medicines and Healthcare products Regulatory Agency, United Kingdom]
NIH Recovery Act Awards Enable Crucial Health Research Technologies
Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants. [National Institutes of Health, United States]
FDA Writes Prescription for IT Innovation
The Food and Drug Administration is prioritizing IT as part of its five-year strategic plan, including accelerating a program to build innovative devices to improve field and laboratory analysis. [Food and Drug Administration, United States]
Secretarial Review and Publication of the Annual Report to Congress Submitted by the Contracted Consensus-Based Entity Regarding Performance Measurement (FR Doc. 2010-26795) [Department of Health and Human Services, United States]
Agency Emergency Information Collection Clearance Request for Public Comment (FR Doc. 2010-26753) [Department of Health and Human Services, United States]

Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings (FR Doc. 2010-26316) [National Institutes of Health, United States]

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings (FR Doc. 2010-26717) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26881) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-26935) [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26497) [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26499) [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26362) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26363) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26317) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26390) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26702) [National Institutes of Health, United States]
National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26706) [National Institutes of Health, United States]

EVENTS (Listed by Date)

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

2010 American Pancreatic Association (APA) Annual Meeting
November 3-6, 2010
Chicago, United States

NEW Third Annual Research Experience of Stem Cells in European (RESCUE) Society Conference
November 8-9, 2010
Oxford, United Kingdom

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

Australasian Pancreatic Club Annual Meeting
November 15-16, 2010
Melbourne, Australia

NEW Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction
January 12-17, 2011
Dillon, United States

Keystone Symposia: Obesity
January 12-17, 2011
Keystone, Colorado

2011 Gastrointestinal Cancers Symposium
January 20-22, 2011
San Francisco, United States

Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, DC, United States

Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference
January 26-27, 2011
Amsterdam, The Netherlands

Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club
February 10-13, 2011
Maradu, India

NEW United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.



Lab Technologist — Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist — Tissue Culture (STEMCELL Technologies)

Product Manager — Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

here to post your career opportunities.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us